Skip to main content
Premium Trial:

Request an Annual Quote

Tempus: Scott Gottlieb

Tempus has named former US Food and Drug Administration Commissioner Scott Gottlieb to its board of directors. Gottlieb headed the FDA from May 2017 until April 2019. In the 2000s, he was the agency's deputy commissioner for medical and scientific affairs and later a senior advisor to the former FDA Commissioner. An internal medicine physician, Gottlieb also had a stint as senior advisor to the administrator for the centers for Medicare and Medicaid Services, where he helped implement the Medicare Part D drug benefit. He also spent 10 years as a venture capitalist with New Enterprise Associates. He remains a resident fellow of the American Enterprise Institute, a conservative think tank.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.